Cancers, Volume 14, Issue 19
2022 October-1 - 424 articles
Cover Story: Hepatocellular carcinoma (HCC) is characterized by poor prognosis and quality of life, with limited treatment options available. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) originally emerged as drugs for the management of diabetes but have also demonstrated an array of extraglycemic effects. Given the presence of the GLP-1 receptor in hepatocytes, data suggest that GLP-1 RAs could regulate molecular pathways that are involved in the pathogenesis of HCC through direct and indirect effects on liver cells, while future studies must assess several aspects of the benefit-to-risk ratio of the use of GLP-1 RAs in patients with HCC. In this review, we discuss the potential role of GLP-1 analogs in the treatment of HCC, focusing on the molecular mechanisms that could justify a possible benefit, but also referring to the potential clinical implications and areas for future research. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.